[1]赵格a,高琼b,余宗涛a,等.肺癌患者血浆miR-3151 表达水平与临床病理特征的相关性研究[J].现代检验医学杂志,2020,35(05):28-32.[doi:10.3969/j.issn.1671-7414.2020.05.008]
　ZHAO Gea,GAO Qiongb,YU Zong-taoa,et al.Study on the Correlation between the Expression of miR-3151 in Plasma and Clinicopathological Features in Patients with Lung Cancer[J].Journal of Modern Laboratory Medicine,2020,35(05):28-32.[doi:10.3969/j.issn.1671-7414.2020.05.008]
点击复制

肺癌患者血浆miR-3151 表达水平与临床病理特征的相关性研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第35卷
期数:
2020年05期
页码:
28-32
栏目:
论著
出版日期:
2020-11-01

文章信息/Info

Title:
Study on the Correlation between the Expression of miR-3151 in Plasma and Clinicopathological Features in Patients with Lung Cancer
文章编号:
1671-7414（2020）05-028-05
作者:
赵格1; 2a; 高琼2b; 余宗涛2a; 彭春艳2a; 张吉才2a
1. 锦州医科大学十堰市太和医院研究生培养基地 湖北医药学院附属医院，湖北十堰 442000； 2. 十堰市太和医院a. 检验部；b. 呼吸内科, 湖北十堰 442000
Author(s):
ZHAO Ge1; 2a;  GAO Qiong2b;  YU Zong-tao2a;  PENG Chun-yan2a;  ZHANG Ji-cai2a
1.Postgraduate Training Basement of Jinzhou Medical University, Taihe Hospital, Hubei University of Medicine, Hubei Shiyan 442000, China;2a.Department of Laboratory Medicine；2b.Department of Respiratory Medicine,Taihe Hospital, Hubei University of Medicine, Hubei Shiyan 442000, China
关键词:
miR-3151; 肺癌; 病理特征; 诊断
分类号:
R734.2;R730.43
DOI:
10.3969/j.issn.1671-7414.2020.05.008
文献标志码:
A
摘要:
目的　探讨肺癌患者血浆中miR-3151 的表达及其与患者临床病理特征的关系。方法　收集十堰市太和医院 2018 年10 月～ 2019 年10 月确诊的120 例肺癌患者（肺癌组）及同期120 例体检健康者（对照组）的血浆样本，实时 荧光定量PCR（quantitative real-time PCR，qRT-PCR）技术检测两组血浆miR-3151 的表达水平，分析血浆miR-3151 的 表达与肺癌患者临床病理特征的关系。受试者工作特征曲线（receiver operating characteristic curve，ROC）用以评估血 浆miR-3151 单独及联合细胞角蛋白19 片段（cytokeratin-19 fragment，CYFRA21-1）、神经元特异性烯醇化酶（neuronspecific enolase，NSE）和癌胚抗原（carcinoembryonic antigen，CEA）对肺癌的诊断价值。结果　肺癌组血浆miR-3151（nmol/ L）显著高于对照组[86.356（19.893，305.155）vs 8.871（4.620，14.037）]，差异有统计学意义（Z=-10.039，P ＜ 0.001）。 血浆miR-3151 的表达上调与肺癌患者淋巴结转移（Z=-2.336，P=0.019）和临床分期（Z=-2.628，P=0.009）相关。血 浆miR-3151,CYFRA21-1,NSE 及CEA 单独用于诊断肺癌的曲线下面积（area under the cure，AUC）分别为0.875（95%CI： 0.830 ～ 0.919），0.704（95%CI：0.639 ～ 0.770），0.769（95%CI：0.707 ～ 0.830）和0.632（95%CI：0.562 ～ 0.702）， 当miR-3151 联合NSE 时，诊断肺癌的AUC 增加至0.909（95%CI：0.872 ～ 0.946），较单独诊断时有明显提高。结论　 miR-3151 在肺癌患者血浆中表达上调，与肿瘤进展相关，有成为肺癌诊断标志物的潜能。
Abstract:
Objective　To explore the expression level of plasma miR-3151 in lung cancer and its relationship with clinicopathological features. Methods　The plasma samples of 120 lung cancer patients(lung cancer group)and 120 healthy subjects (control group) were collected from Taihe Hospital of Shiyan City from October 2018 to October 2019. Quantitative real-time polymerase chain reaction(qRT-PCR) was used to detect the expression level of plasma miR-3151 in the two groups. The clinical data of lung cancer patients were analyzed to explore the correlation between plasma miR-3151 and clinicopathological features. Receiver operating characteristic (ROC) curve was used to evaluate the diagnostic value of plasma miR-3151, cytokeratin 19 fragment (CYFRA21-1), neuron specific enolase (NSE) and carcinoembryonic antigen (CEA) for lung cancer. Results　The expression level of plasma miR-3151 (nmol/L)in lung cancer group was obviously higher than that in control group[86.356 (19.893,305.155) vs 8.871 (4.620 ,14.037)], and the difference was statistically significant (Z=-10.039，P ＜ 0.001). The upregulation of plasma miR-3151 showed association with the lymph node metastasis(Z=-2.336，P=0.019) and clinical stage(Z=-2.628，P=0.009)of patients with lung cancer. The area under the curve (AUC) of plasma miR-3151, CYFRA21-1, NSE and CEA for the diagnosis of lung cancer were 0.875 (95%CI:0.830~0.919), 0.704 (95%CI:0.639~0.770), 0.769 (95%CI:0.707~0.830) and 0.632 (95%CI:0.562~0.702), respectively. When miR-3151 combined with NSE, the AUC for diagnosis of lung cancer increased to 0.909 (95%CI:0.872~0.946), which was significantly higher than that of diagnosis alone. Conclusion　The expression of plasma miR-3151 in lung cancer was up-regulated, which was related to tumor progression, and it has the potential to become a diagnostic marker for lung cancer.

参考文献/References:

[1]　 BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA-A Cancer Journal for Clinicians, 2018, 68(6): 394-424.
[2]　 DE PLANELL-SAGUER M, RODICIO M C . Detection methods for microRNAs in clinic practice [J]. Clinical Biochemistry, 2013, 46(10/11): 869-878.
[3]　 PENG Yong, CROCE C M. The role of microRNAs in human cancer[J]. Signal Transduct Target Ther, 2016, 1:15004.
[4]　 LIN Shuibin, GREGORY R I. MicroRNA biogenesis pathways in cancer[J]. Nature Reviews Cancer, 2015,15(6):321-333.
[5]　 CALIN G A, SEVIGNANI C, DUMITRU C D, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers[J]. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101(9): 2999-3004.
[6]　 LIU Tianchi, WU Xiaoping, CHEN Tong , et al. Downregulation of DNMT3A by miR-708-5p inhibits lung cancer stem cell-like phenotypes through repressing Wnt/β-catenin signaling [J]. Clinical cancer research, 2018, 24(7): 1748-1760.
[7]　 PALIOURAS A R , MONTEVERDE T, GAROFALO M . Oncogene-induced Regulation of microRNA expression: implications for cancer initiation, progression and therapy [J]. Cancer Lett, 2018,421:152-160.
[8]　 WANG Hao, PENG Ran, WANG Junjie, et al. Circulating microRNAs as potential cancer biomarkers: the advantage and disadvantage [J]. Clin Epigenetics， 2018, 10: 59.
[9]　 冯磊， 常春红， 管晓卿， 等． 宫颈癌患者血浆 miRNA-10b 的表达及其临床意义[J]．现代检验医 学杂志, 2018, 33（1）: 52-55, 58． 　　 FENG Lei, CHANG Chunhong, GUAN Xiaoqing, et al. Expression of plasma miRNA-10b in patients with cervical cancer and its clinical significance[J]. Journal of Modern Laboratory Medicine, 2018，33（1）：52- 55, 58．
[10] 黄刚，陈霏，肇玉博，等．非小细胞肺癌患者血浆 miRNA-145 和miRNA-221 表达与临床特征及术后 复发的相关性研究[J]．现代检验医学杂志, 2019, 34（4）: 40-44． 　　 HUANG Gang, CHEN Fei, ZHAO Yubo, et al. Study on the correlation between the expression of microRNA145 and microRNA221 in plasma and clinical characteristics and postoperative recurrence in patients with non-small cell lung cancer [J]. Journal of Modern Laboratory Medicine, 2019,34(4):40-44.　
[11] EISFELD A K, SCHWIND S, PATEL R, et al. Intronic miR-3151 within BAALC drives leukemogenesis by deregulating the TP53 pathway[J]. Science Signaling, 2014, 7(321): a36.
[12] EISFELD A K, MARCUCCI G, MAHARRY K, et al. MiR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia[J]. Blood, 2012, 120(2): 249-258.
[13] D?AZ-BEY? M,BRUNET S,NOMDED?U J, et al. The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia[J]. Blood Cancer Journal, 2015，5(10):e352
[14] LANKENAU M A, PATEL R, LIYANARACHCHI S, et al. MicroRNA-3151 inactivates TP53 in BRAFmutated human malignancies[J]. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112(49): E6744-E6751.

相似文献/References:

[1]马丽颜,梁 静,周建龙.腺瘤样结肠息肉易感基因(APC)及结直肠癌缺失基因(DCC)基因甲基化在肺癌早期诊断的意义[J].现代检验医学杂志,2016,31(01):17.[doi:10.3969/j.issn.1671-7414.2016.01.005]
　MA Li-yan,LIANG Jing,ZHOU Jian-long.Evaluation of the Combination of APC and DCC Gene Methylation in the Early Diagnosis of Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(05):17.[doi:10.3969/j.issn.1671-7414.2016.01.005]
[2]彭 瑛,邓正华,温先勇.国内13种血清肿瘤标志物对肺癌诊断价值的Meta分析[J].现代检验医学杂志,2016,31(01):96.[doi:10.3969/j.issn.1671-7414.2016.01.028]
　PENG Ying,DENG Zheng-hua,WEN Xian-yong.Diagnostic Value of Thirteen Types of Serum Tumor Markers for Lung Cancer in China:A Meta-Analysis[J].Journal of Modern Laboratory Medicine,2016,31(05):96.[doi:10.3969/j.issn.1671-7414.2016.01.028]
[3]翟海军,朱晶.红细胞分布宽度对肺癌预后的临床分析[J].现代检验医学杂志,2015,30(06):147.[doi:10.3969/j.issn.1671-7414.2015.06.045]
　ZHAI Hai-jun,ZHU Jing.Clinical Analysis of Red Blood Cell Distribution Width on the Prognosis of Lung Cancer[J].Journal of Modern Laboratory Medicine,2015,30(05):147.[doi:10.3969/j.issn.1671-7414.2015.06.045]
[4]姜 波,王玉明,段 勇.肺癌组织中调控PUMA基因 的miRNA筛查和MiR-221表达差异研究[J].现代检验医学杂志,2015,30(01):15.[doi:10.3969/j.issn.1671-7414.2015.01.005]
　JIANG Bo,WANG Yu-ming,DUAN Yong.Study on the Differential Expression of miRNA Screening and MiR-221 Regulates Apoptosis by Targeting PUMA Gene in Lung Cancer[J].Journal of Modern Laboratory Medicine,2015,30(05):15.[doi:10.3969/j.issn.1671-7414.2015.01.005]
[5]赵车冬,闫玉珠,吴文婧,等.血清CEA,CYFRA21-1,NSE水平在肺癌诊断与分型中的应用价值[J].现代检验医学杂志,2016,31(06):59.[doi:10.3969/j.issn.1671-7414.2016.06.016]
　ZHAO Che-dong,YAN Yu-zhu,WU Wen-jing,et al.Application Value of Serum CEA,CYFRA21-1 and NSE Levels in the Diagnosis and Typing of Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(05):59.[doi:10.3969/j.issn.1671-7414.2016.06.016]
[6]董 莉,张保平,冯新平,等.血浆HSP90α检测在肺癌诊断中的临床应用价值研究[J].现代检验医学杂志,2017,32(04):97.[doi:10.3969/j.issn.1671-7414.2017.04.027]
　DONG Li,ZHANG Bao-ping,FENG Xin-ping,et al.Plasma HSP90 Alpha Testing Clinical Application Value in the Diagnosis of Lung Cancer Researc[J].Journal of Modern Laboratory Medicine,2017,32(05):97.[doi:10.3969/j.issn.1671-7414.2017.04.027]
[7]张利祥,潘 静,赵 洁,等.痰液基细胞学检查与血清CYFRA21-1,CEA,NSE联合检测对肺癌的诊断价值[J].现代检验医学杂志,2019,34(03):99.[doi:10.3969/j.issn.1671-7414.2019.03.024]
　ZHANG Li-xiang,PAN Jing,ZHAO Jie,et al.Value of the Combined Determination of Sputum Liquid-Based Cytologyand Serum CYFRA21-1,CEA,NSE for the Diagnosis of Lung Cancer[J].Journal of Modern Laboratory Medicine,2019,34(05):99.[doi:10.3969/j.issn.1671-7414.2019.03.024]
[8]樊　华,弥　鹏,杨　波,等.肺癌患者外周血血小板参数检测分析及临床意义[J].现代检验医学杂志,2019,34(06):97.[doi:10.3969 ／ j.issn.1671-7414.2019.06.024]
　FAN Hua,MI Peng,YANG Bo,et al.Analysis and Clinical Value of Peripheral Platelet Parameters in Lung Cancer Patients[J].Journal of Modern Laboratory Medicine,2019,34(05):97.[doi:10.3969 ／ j.issn.1671-7414.2019.06.024]
[9]毛　俊,王　柯.老年肺癌患者肺切除术后血液 CRP，D- 二聚体，IL-17 水平与并发急性呼吸衰竭的相关性研究[J].现代检验医学杂志,2021,36(03):83.[doi:10.3969/j.issn.1671-7414.2021.03.019]
　MAO Jun,WANG Ke.Correlation of Blood CRP, D-dimer and IL-17 Levels with Acute RespiratoryFailure in Elderly Patients with Lung Cancer after Pneumonectomy[J].Journal of Modern Laboratory Medicine,2021,36(05):83.[doi:10.3969/j.issn.1671-7414.2021.03.019]
[10]李　辉,汪春新,秦明明,等.肺癌患者血清7项肿瘤标志物联合检测在病理分型及临床分期中的应用价值研究[J].现代检验医学杂志,2021,36(04):5.[doi:10.3969/j.issn.1671-7414.2021.04.002]
　LI Hui,WANG Chun-xin,QIN Ming-ming,et al.Study on the Application Value of Combined Detection of 7 Tumor Markersin Serum of Patients with Lung Cancer in Pathological Classificationand Clinical Staging[J].Journal of Modern Laboratory Medicine,2021,36(05):5.[doi:10.3969/j.issn.1671-7414.2021.04.002]

备注/Memo

备注/Memo:
作者简介：赵格（1992-），女，硕士在读，主要从事肿瘤分子诊断研究，E-mail:zhaogegege1992@163.com。
通讯作者：张吉才，男, 主任技师，硕士生导师，主要从事基因异常甲基化与肿瘤研究，E-mail:3561361@qq.com。
更新日期/Last Update: 2020-10-30